Stanford Finds Drug That Preserves Muscle in GLP-1 Weight Loss, Restoring Strength in 25% Slimmed Mice
Updated
Updated · Stanford Medical Center Report · Jun 2
Stanford Finds Drug That Preserves Muscle in GLP-1 Weight Loss, Restoring Strength in 25% Slimmed Mice
3 articles · Updated · Stanford Medical Center Report · Jun 2
Summary
Stanford researchers reported that an experimental 15-PGDH inhibitor improved muscle regeneration and post-injury strength in obese mice treated with semaglutide, addressing a key side effect of GLP-1 weight-loss drugs.
In the study, semaglutide cut body weight by about 25% and reduced fat, but also lowered skeletal muscle mass and impaired recovery after muscle damage; adding the inhibitor preserved repair capacity without blunting fat loss.
The compound boosted muscle stem-cell proliferation and restored new muscle-fiber formation, while showing no strength benefit in healthy young mice unless muscle had been damaged.
MF-300, an oral version of the inhibitor, has completed Phase 1 safety testing in humans and is slated for Phase 2b sarcopenia trials later this year.
The June 2 PNAS study suggests the drug could eventually be paired with GLP-1 therapies—or other major weight-loss regimens—to limit lean-mass loss, though it has not yet been tested in older obese people.
Is a pill to fix a pill's side effect the future of weight loss or a dangerous shortcut?
This drug saves muscle by boosting a key metabolite. What are the hidden long-term risks?
Preserving Muscle During GLP-1 Weight Loss: MF-300 and the Future of Fat-Specific Obesity Therapies
Overview
GLP-1 weight loss medications are highly effective for fat loss, but their widespread use has revealed a major problem: they also cause significant muscle loss, which can harm strength, mobility, and overall health. Recognizing this urgent need, Stanford researchers discovered that a 15-PGDH inhibitor called MF-300 can help preserve and even restore muscle during GLP-1 treatment. This breakthrough offers hope for healthier weight loss by allowing patients to lose fat without sacrificing vital muscle mass, addressing a key challenge in current obesity therapies.